Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 3
1998 3
1999 4
2001 15
2002 9
2003 12
2004 13
2005 15
2006 18
2007 19
2008 24
2009 17
2010 22
2011 22
2012 18
2013 16
2014 18
2015 13
2016 11
2017 12
2018 18
2019 13
2020 7
2021 7
2022 7
2023 9
2024 1
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

302 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Tolterodine extended release is well tolerated in older subjects.
Griebling TL, Kraus SR, Richter HE, Glasser DB, Carlsson M. Griebling TL, et al. Int J Clin Pract. 2009 Aug;63(8):1198-204. doi: 10.1111/j.1742-1241.2009.02108.x. Int J Clin Pract. 2009. PMID: 19624787 Free PMC article.

Dry mouth was the only AE consistently associated with tolterodine ER treatment (< 65 years, 17%; 65-74 years, 16%; > or = 75 years, 15%). The occurrence of all other AEs was < or = 5% in most age and treatment cohorts. ...CONCLUSION: The nature and frequency of A

…
Dry mouth was the only AE consistently associated with tolterodine ER treatment (< 65 years, 17%; 65-74 years, 16%; > or = 75 y …
Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data.
Nilvebrant L, Hallén B, Larsson G. Nilvebrant L, et al. Life Sci. 1997;60(13-14):1129-36. doi: 10.1016/s0024-3205(97)00057-x. Life Sci. 1997. PMID: 9121357 Review.
A major active metabolite, (PNU-200577) the 5-hydroxymethyl derivative of tolterodine, has a similar pharmacological profile. Based on pharmacological and pharmacokinetic data, it has been concluded that this metabolite contributes significantly to the therapeutic effect o …
A major active metabolite, (PNU-200577) the 5-hydroxymethyl derivative of tolterodine, has a similar pharmacological profile. Based o …
Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis.
Harvey MA, Baker K, Wells GA. Harvey MA, et al. Am J Obstet Gynecol. 2001 Jul;185(1):56-61. doi: 10.1067/mob.2001.116371. Am J Obstet Gynecol. 2001. PMID: 11483904
OBJECTIVE: To compare tolterodine with oxybutynin in treatment of urge incontinence. STUDY DESIGN: A systematic review, following Cochrane methods, was performed to retrieve results of randomized trials that compared tolterodine with oxybutynin in adults with urge i …
OBJECTIVE: To compare tolterodine with oxybutynin in treatment of urge incontinence. STUDY DESIGN: A systematic review, following Coc …
Comparison of the efficacy and complications of tolterodine and alpha-adrenergic receptor blockers in improving ureteral stent-related symptoms: A systematic review and meta-analysis.
Liu M, Liu S, Mao Q, Zou Q, Cui Y, Wu J. Liu M, et al. PLoS One. 2024 May 3;19(5):e0302716. doi: 10.1371/journal.pone.0302716. eCollection 2024. PLoS One. 2024. PMID: 38701097 Free PMC article.
OBJECTIVE: We conducted a systematic evaluation of the therapeutic efficacy and complications of tolterodine and alpha-adrenergic receptor blockers in alleviating ureteral stent-related symptoms. ...CONCLUSION: This meta-analysis suggests that tolterodine is superio …
OBJECTIVE: We conducted a systematic evaluation of the therapeutic efficacy and complications of tolterodine and alpha-adrenergic rec …
Comparisons of Therapeutic Efficacy and Safety of Solifenacin versus Tolterodine in Patients with Overactive Bladder: A Meta-Analysis.
Wang HT, Xia M. Wang HT, et al. Urol Int. 2019;103(2):187-194. doi: 10.1159/000497311. Epub 2019 Jun 6. Urol Int. 2019. PMID: 31170710
Moreover, no significant difference was obtained in the incidence of dry mouth between solifenacin and tolterodine at 8 and 12 weeks of follow-up. However, tolterodine decreased the constipation rate at 12 weeks compared with solifenacin. ...However, tolterodine …
Moreover, no significant difference was obtained in the incidence of dry mouth between solifenacin and tolterodine at 8 and 12 weeks …
[Safety of solifenacin and tolterodine in the treatment of overactive bladder: a meta-analysis].
Xu C, Jiang XZ, Zhang NZ, Zhao HF, Xu ZS. Xu C, et al. Zhonghua Yi Xue Za Zhi. 2012 Dec 25;92(48):3398-402. Zhonghua Yi Xue Za Zhi. 2012. PMID: 23327698 Chinese.
OBJECTIVE: To evaluate the safety of solifenacin and tolterodine in the treatment of overactive bladder (OAB). METHODS: Studies on the solifenacin, tolterodine and OAB were searched and those fulfilling the inclusion criteria were selected. ...CONCLUSIONS: Dry mouth …
OBJECTIVE: To evaluate the safety of solifenacin and tolterodine in the treatment of overactive bladder (OAB). METHODS: Studies on th …
Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.
He W, Huang G, Cui W, Tian Y, Sun Q, Zhao X, Zhao Y, Li D, Liu X. He W, et al. Int Braz J Urol. 2023 Sep-Oct;49(5):535-563. doi: 10.1590/S1677-5538.IBJU.2023.0158. Int Braz J Urol. 2023. PMID: 37506033 Free PMC article.
In terms of safety, solifenacin 5mg, ER-tolterodine 4mg, mirabegron, vibegron and ER-oxybutynin 10mg all showed a better incidence of dry mouth, fesoterodine 4mg, ER-oxybutynin 10mg, tolterodine 2mg, and vibegron in the incidence of constipation. ...
In terms of safety, solifenacin 5mg, ER-tolterodine 4mg, mirabegron, vibegron and ER-oxybutynin 10mg all showed a better incidence of …
International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
Staskin D, Frankel J, Varano S, Shortino D, Jankowich R, Mudd PN Jr. Staskin D, et al. J Urol. 2020 Aug;204(2):316-324. doi: 10.1097/JU.0000000000000807. Epub 2020 Feb 18. J Urol. 2020. PMID: 32068484 Clinical Trial.
MATERIALS AND METHODS: Adult patients with overactive bladder with 8.0 or more micturitions per day were randomized 5:5:4 to 75 mg vibegron, placebo or extended-release 4 mg extended-release tolterodine. Up to 25% of patients could have dry overactive bladder (less than 1. …
MATERIALS AND METHODS: Adult patients with overactive bladder with 8.0 or more micturitions per day were randomized 5:5:4 to 75 mg vibegron, …
Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine.
Sebastianelli A, Russo GI, Kaplan SA, McVary KT, Moncada I, Gravas S, Chapple C, Morgia G, Serni S, Gacci M. Sebastianelli A, et al. Int J Urol. 2018 Mar;25(3):196-205. doi: 10.1111/iju.13498. Epub 2017 Dec 3. Int J Urol. 2018. PMID: 29205506
Both mirabegron 50 mg and mirabegron 100 mg were associated with a significant reduction of nocturia episodes when compared with a placebo. Conversely, tolterodine 4 mg did not prove to be more effective than a placebo in the reduction of nocturia episodes. ...Otherwise, …
Both mirabegron 50 mg and mirabegron 100 mg were associated with a significant reduction of nocturia episodes when compared with a placebo. …
Desmopressin Plus Tolterodine vs Desmopressin Plus Indomethacin for Refractory Pediatric Enuresis: An Open-label Randomized Controlled Trial.
Esteghamati M, Mousavi SE, Zoghi G. Esteghamati M, et al. Indian Pediatr. 2023 Jun 15;60(6):447-451. Epub 2023 Apr 20. Indian Pediatr. 2023. PMID: 37078485 Free article. Clinical Trial.
OBJECTIVE: To compare the efficacy of desmopressin plus tolterodine (D+T) with desmopressin plus indomethacin (D+I) for treating enuresis in children. ...INTERVENTION: Patients were randomized to receive either D+T (60 g sublingual desmopressin and 2 mg tolterodine …
OBJECTIVE: To compare the efficacy of desmopressin plus tolterodine (D+T) with desmopressin plus indomethacin (D+I) for treating enur …
302 results